Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

Kensei Tobinai, Yukio Kobayashi, Masaru Narabayashi, +8

Annals of Oncology

B-cell LymphomaLymphoid NeoplasiaHematological MalignancyMedicineImmunology +5

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

Tomofumi Igarashi, Yukio Kobayashi, Michinori Ogura, +15

Annals of Oncology

Hematological MalignancyIndolent B-cell LymphomaProgression-free SurvivalLymphoid NeoplasiaMedicine +8

Role of Interleukin-18 and T-helper Type 1 Cytokines in the Development of Mycoplasma pneumoniae Pneumonia in Adults

Hiroshi Tanaka, Mitsuo Narita, Shin Teramoto, +4

CHEST Journal

Clinical ImmunologyCytokineImmunodeficienciesImmunologyRespiratory Infection +6

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

Kensei Tobinai, Tomofumi Igarashi, Kuniaki Itoh, +12

Annals of Oncology

Hematological MalignancyLymphoid NeoplasiaAggressive B-cell LymphomaMedicineMalignant Blood Disorder +8

Measurement of bronchial hyperreactivity in infants and preschool children using a new method.

Gyokei Murakami, Tomofumi Igarashi, Yoko Adachi, +5

PubMed

AsthmaNeonatologyPediatric Lung DiseasePreschool ChildrenNew Method +15

Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations

Kuniaki Itoh, Yosuke Sasaki, Hirofumi Fujii, +4

British Journal of Cancer

Anti-cancer AgentsClinical Trial DesignMedicineCancer ManagementPharmacotherapy +7

Granulocyte Colony-Stimulating Factor-Producing Large Cell Undifferentiated Carcinoma of the Lung.

Noriharu Shijubo, Michio Hirasawa, Tomofumi Igarashi, +4

Internal Medicine

Tumoral PathologyMalignant DiseaseGranulocyteMedicineImmunology +13

Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.

Hironobu Minami, Hirofumi Fujii, Tomofumi Igarashi, +4

PubMed

Acid fog and hospital visits for asthma: an epidemiological study

Hiroshi Tanaka, S Honma, Motoi Nishi, +4

European Respiratory Journal

Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.

Kunio Itoh, Y. Sasaki, Hisaki Fujii, +8

PubMed

Doxorubicin AdministrationAdvanced Breast CancerBreast OncologyDose EscalationMedicine +10